(CercleFinance.com) – Due to the temporary suspension of the implantations of its Aeson artificial heart, CARMAT did not record any turnover during the 1st half of 2022.
The company has endeavored to control its expenses, so that the operating loss for the 1st half of 2022 amounts to 25.1 ME. After taking into account the financial result (-1.9 ME) and the research tax credit (+E0.9 ME), the net loss for the 1st half amounted to 26.0 ME.
The company’s cash at June 30, 2022 stood at €47.4 million, compared to €39.2 million at December 31, 2021. Its increase of €8.2 million during the 1st half of 2022 is explained by a change in flows of + 8.2% including, in April, fundraising for an amount of 40.5 ME.
The resources available to CARMAT should allow it to finance its activities until March 2023. The company is confident that it will obtain the necessary resources to continue its development and the marketing of Aeson.
The company expects a resumption of settlements in October 2022, after obtaining the green light from the authorities.
“We have focused our efforts on our goal of restarting Aeson heart implants. We were able to restart production at the end of March after having implemented the necessary changes in our production chain,” underlines Stéphane Piat, managing director of Carmat.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
Are you following this action?
Receive all the information about CARMAT in real time: